SPDL1 and non-small cell lung carcinoma: As reported by Himuro et al. [36], increased sPD-L1 levels at baseline were significantly correlated with worse PFS and OS in NSCLC patients receiving ICI monotherapy but not in those receiving ICIs-chemotherapy combinations, while higher posttreatment sPD-1 and PD-L1 levels were predictive of improved and worse OS, respectively, suggesting, as emphasized by the authors, that both pretreatment sPD-L1, as well as posttreatment sPD-1 and sPD-L1, may represent useful prognostic biomarkers in this setting.